The rumored acquisition of Bristol-Myers Squibb by GlaxoSmithKline would be the latest and largest ripple effect from the Bristol/Squibb integration in 1989. The two CEOs who drove the Glaxo/SmithKline merger at the end of the 1990s (Glaxo's Richard Sykes and SmithKline's Jan Leschly) were both former Squibb execs who learned firsthand the perils of a lack of scale during a period of consolidation. While both Sykes and Leschly have retired, the logic and momentum behind the strategy they pursued is a prime factor driving GSK's interest in Bristol...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”